Abstract
Object
The authors present a safety evaluation of the perioperative use of recombinant activated factor VII (rFVIIa) in a series of subarachnoid hemorrhage patients undergoing microsurgical aneurysm clipping.
Methods
We performed a retrospective chart review of the records of 18 consecutive subarachnoid hemorrhage patients who underwent craniotomy for aneurysm clipping and received an intraoperative dose of rFVIIa. In each case, the aneurysm was felt to be a “high risk” lesion for intraoperative rupture either because it had bled multiple times prior to surgery or based on anatomical considerations. All complications were recorded whether or not they were attributed to the use of rFVIIa.
Results
Eighteen patients, 7 men and 11 women, ranging in age from 42 to 85 years were included in this review. Nine patients (50%) were either Hunt/Hess Grades IV or V. Six patients developed clinically significant cerebral vasospasm. Fifteen patients required ventricular drainage on admission, and seven patients ultimately required a ventriculoperitoneal shunt. One lower extremity deep venous thrombosis and seven upper extremity venous thromboses in association with peripherally inserted central catheter (PICC) lines were identified on screening Doppler evaluations. There were no associated pulmonary emboli. No aneurysm ruptured intraoperatively.
Conclusion
We describe our experience with the use of a single dose of rFVIIa administered perioperatively in an attempt to decrease the rate of intraoperative aneurysm rupture in patients undergoing microsurgical aneurysm clipping. There were no significant immediate or long-term adverse effects attributable to the use of rFVIIa in this group, and we encountered no intraoperative ruptures in this relatively small series.
Similar content being viewed by others
References
Adams HP Jr, Kassell NF, Torner JC, Nibbelink DW, Sahs AL. Early management of aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study. J Neurosurg. 1981;54:141–5.
Arkin S, Cooper HA, Hutter JJ, Miller S, Schmidt ML, Seibel NL, et al. Activated recombinant human coagulation factorVII therapy for intracranial hemorrhage in patients with hemophilia A or B with inhibitors. Results of the NovoSeven emergency-use program. Haemostasis. 1998;28:93–8. doi:10.1159/000022418.
Batjer HH, Samson DS. Intraoperative aneurysmal rupture: incidence, outcome, and suggestions for surgical management. Neurosurgery. 1986;18:701–7.
Brott T, Broderick J, Kothari R, Barsan W, Tomsick T, Sauerbeck L, et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke. 1997;28:1–5.
Chwajol M, Starke RM, Kim GH, Mayer SA, Connolly ES. Antifibrinolytic therapy to prevent early rebleeding after subarachnoid hemorrhage. Neurocrit Care. 2008;8:418–26. doi:10.1007/s12028-008-9088-5.
Dutton RP, McCunn M, Hyder M, D’Angelo M, O’Connor J, Hess JR, et al. Factor VIIa for correction of traumatic coagulopathy. J Trauma Inj Infect Crit Care. 2004;57:709–19. doi:10.1097/01.TA.0000140646.66852.AB.
Elijovich L, Higashida RT, Lawton MT, Duckwiler G, Giannotta S, Johnston C. Predictors and outcomes of intraprocedural rupture in patients treated for ruptured intracranial aneurysms. The CARAT study. Stroke. 2008;39:1501–6. doi:10.1161/STROKEAHA.107.504670.
Fewel ME, Park P. The emerging role of recombinant-activated factor VII in neurocritical care. Neurocrit Care. 2004;1:19–30. doi:10.1385/NCC:1:1:19.
Giannotta SL, Oppenheimer JH, Levy ML, Zelman V. Management of intraoperative rupture of aneurysm without hypotension. Neurosurgery. 1991;28:531–6. doi:10.1097/00006123-199104000-00008.
Gibbs JR, Corkill AGL. Use of antifibrinolytic agent (tranexamic acid) in the management of ruptured intracranial aneurysm. Postgrad Med J. 1971;47:199–200.
Hawryluk GWJ, Cusimano MD. The role of recombinant factor VII in neurosurgery: hope or hype. J Neurosurg. 2006;105:859–68. doi:10.3171/jns.2006.105.6.859.
Hedner U. Dosing with recombinant Factor VIIa based on current evidence. Semin Hematol. 2004;41:35–9. doi:10.1053/j.seminhematol.2003.11.008.
Hillman J, Fridriksson S, Nilsson O, Yu Z, Saveland H, Jakobsson KE. Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study. J Neurosurg. 2002;97:771–8.
Hoffman M, Monroe DM III. A cell-based model of hemostasis. Thromb Haemost. 2001;85:958–65.
Ingerslev J. Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VII and factor IX inhibitors. Semin Thromb Hemost. 2000;26:425–32. doi:10.1055/s-2000-8463.
Komotar RJ, Hahn DK, Kim GH, Khandji J, Mocco J, Mayer SA, et al. The impact of microsurgical fenestration of the lamina terminalis on shunt-dependent hydrocephalus and vasospasm after aneurysmal subarachnoid hemorrhage. Neurosurgery. 2008;62:123–32.
Lawton MT, Du R. Effect of the neurosurgeon’s surgical experience on outcomes from intraoperative aneurysm rupture. Neurosurgery. 2005;57:9–15. doi:10.1227/01.NEU.0000163082.20941.EF.
Leipzig TJ, Redelman K, Horner TG. Reducing the risk of rebleeding before early aneurysm surgery: a possible role for antifibrinolytic therapy. J Neurosurg. 1997;86:220–5.
Leipzig TJ, Morgan J, Horner TG, Payner T, Redelman K, Johnson CS. Analysis of intraoperative rupture in the surgical treatment of 1694 saccular aneurysms. Neurosurgery. 2005;56:455–68. doi:10.1227/01.NEU.0000154697.75300.C2.
Lin J, Hanigan WC, Tarantino M, Wang J. The use of recombinant activated factor VII to reverse warfarin-induced anticoagulation in patients with hemorrhages in the central nervous system: preliminary findings. J Neurosurg. 2003;98:737–40.
Macdonald RL. Lumbar drainage after subarachnoid hemorrhage: does it reduce vasospasm and delayed hydrocephalus? Neurocrit Care. 2007;7:1–2. doi:10.1007/s12028-007-0046-4.
Martinowitz U, Kenet G, Segal E, Luboshitz J, Lubetsky A, Ingerslev J, et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma. 2001;51:431–9. doi:10.1097/00005373-200109000-00002.
Mayer SA. Ultra-early hemostatic therapy for intracerebral hemorrhage. Stroke. 2003;34:224–9. doi:10.1161/01.STR.0000046458.67968.E4.
Mayer SA, Brun NC, Broderick J, Davis S, Diringer MN, Skolnick BE, et al. Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage. Stroke. 2005;36:74–9. doi:10.1161/01.STR.0000149628.80251.b8.
Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005;352:777–85. doi:10.1056/NEJMoa042991.
Morenski JD, Tobias JD, Jimenez DF. Recombinant activated factor VII for cerebral injury-induced coagulopathy in pediatric patients. Report of three cases and review of the literature. J Neurosurg. 2003;98:611–6.
Mullan S, Dawley J. Antifibrinolytic therapy for intracranial aneurysm. J Neurosurg. 1968;28:21–3.
Nibbelink DW, Torner JC, Henderson WG. Intracranial aneurysms and subarachnoid hemorrhage. A cooperative study. Antifibrinolytic therapy in recent onset subarachnoid hemorrhage. Stroke. 1975;6:622–9.
Norlen G, Thulin CA. The use of antifibrinolytic substances in ruptured intracranial aneurysms. Neurochirurgia (Stuttg). 1969;12:100–2.
Nussbaum ES, Sebring LA, Ostanny I, Nelson WB. Transient cardiac standstill induced by adenosine in the management of intraoperative aneurysmal rupture: technical case report. Neurosurgery. 2000;47:240–3. doi:10.1097/00006123-200007000-00053.
O’Neill PA, Bluth M, Gloster ES, Wali D, Priovolos S, DiMaio TM, et al. Successful use of recombinant activated factor VII for trauma-associated hemorrhage in a patient without preexisting coagulopathy. J Trauma. 2002;52:400–5. doi:10.1097/00005373-200202000-00034.
Parameswaran R, Shapiro AD, Gill JC, Kessler CM. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia Research Society Registry. Haemophilia. 2005;11:100–16. doi:10.1111/j.1365-2516.2005.01075.x.
Park P, Fewel ME, Garton HJ, Thompson BG, Hoff JT. Recombinant activated factor VII for the rapid correction of coagulopathy in nonhemophilic neurosurgical patients. Neurosurgery. 2003;53:34–9. doi:10.1227/01.NEU.0000068830.54968.A8.
Pickard JD, Kirkpatrick PJ, Melsen T, Andreasen RB, Gelling L, Fryer T, et al. Potential role of NovoSeven in the prevention of rebleeding following aneurysmal subarachnoid haemorrhage. Blood Coagul Fibrinolysis. 2000;11:S117–20.
Rizoli SB, Nascimiento B Jr, Osman F, Netto FS, Kiss A, Callum J, et al. Recombinant activated coagulation factor VII and bleeding trauma patients. J Trauma. 2006;61:1419–25. doi:10.1097/01.ta.0000243045.56579.74.
Roos Y. Antifibrinolytic treatment in subarachnoid hemorrhage: a randomized placebo-controlled trial. STAR Study Group. Neurology. 2000;54:77–82.
Roos Y, Rinkel G, Vermeulen M, Algra A, van Gijn J. Antifibrinolytic therapy for aneurysmal subarachnoid hemorrhage: a major update of a cochrane review. Stroke. 2003;34:2308–9. doi:10.1161/01.STR.0000089030.04120.0E.
Schramm J, Cedzich C. Outcome and management of intraoperative aneurysm rupture. Surg Neurol. 1993;40:26–30. doi:10.1016/0090-3019(93)90165-W.
Sorensen B, Johansen P, Nielsen GL, Sorensen JC, Ingerslev J. Reversal of the international normalized ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects. Blood Coagul Fibrinolysis. 2003;14:469–77. doi:10.1097/00001721-200307000-00007.
Subramaniam S, Demchuk AM, Watson T, Barber PA, Hill MD. Unexpected posthemorrhagic hydrocephalus in patients treated with rFVIIa. Neurology. 2006;67:1096–9. doi:10.1212/01.wnl.0000237321.60852.e7.
Tovi D. The use of antifibrinolytic drugs to prevent early recurrent aneurismal subarachnoid hemorrhage. Acta Neurol Scand. 1973;49:163–75.
Tsementzis SA, Hitchcock ER, Meyer CH. Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms. A double-blind placebo-controlled study. Acta Neurochir (Wien). 1990;102:1–10. doi:10.1007/BF01402177.
Varelas P, Helms A, Sinson G, Spanaki M, Hacein-Bey L. Clipping or coiling of ruptured cerebral aneurysms and shunt-dependent hydrocephalus. Neurocrit Care. 2006;4:223–8. doi:10.1385/NCC:4:3:223.
Vermeulen M, Lindsay KW, Murray GD, Cheah F, Hijdra A, Muizelaar JP, et al. Antifibrinolytic treatment in subarachnoid hemorrhage. N Engl J Med. 1984;311:432–7.
Veshchev I, Elran H, Salame K. Recombinant coagulation factor VIIa for rapid preoperative correction of warfarin-related coagulopathy in patients with acute subdural hematoma. Med Sci Monit. 2002;8:CS98–100.
Wijdicks EF, Hasan D, Lindsay KW, Brouwers PJ, Hatfield R, Murray GD, et al. Short-term tranexamic acid treatment in aneurysmal subarachnoid hemorrhage. Stroke. 1989;20:1674–9.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nussbaum, E.S., Janjua, T.M., Defillo, A. et al. Perioperative Use of Recombinant Factor VII to Prevent Intraoperative Aneurysm Rupture in High Risk Patients: A Preliminary Safety Evaluation. Neurocrit Care 10, 55–60 (2009). https://doi.org/10.1007/s12028-008-9149-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12028-008-9149-9